Paolo Tarantino· @PTarantinoMD · X·· 21 小时前评分70
正文 · 原文
Very promising randomized results with the CDK4 selective inhibitor atirmociclib presented by @antgiorda. Next gen CDKs are here! #ESMO26 #ESMOAmbassadors
129 浏览 · 0 赞 · 1 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.org🔹CDK4 selective inh Atirmociclib + fulvestrant improved mPFS vs investigator’s choice post-CDK4/6i in the FourLight-1 ph2 trial 🔹Neutropenia the most frequent AE & 1 related pneumontis death 🔹Next step: the FourLight-3 ph3 study in the 1L vs CDK4/6i #ESMO26 #ESMOAmbassadors在 X 查看被引用的帖子
来源：Paolo Tarantino · x.com